Oral health might have an impact on heart health, a new study has found. Folks treated for an irregular heart rhythm were more likely to keep a healthy heartbeat if they took steps to manage their gum disease, researchers report. The study involved atrial fibrillation (A-Fib) patients who received catheter ablation, a procedure in which…  read on >  read on >

Phillips Respironics, the company responsible for the recall of millions of defective sleep apnea machines since 2021, must overhaul its production of the machines before it can resume making them in the United States, federal officials announced Tuesday. Under a settlement reached with the company, Phillips must revamp its manufacturing and quality control systems and…  read on >  read on >

The Environmental Protection Agency announced Wednesday that it has finalized a first-ever rule that will drastically lower the amount of PFAS, also known as “forever chemicals,” in the nation’s drinking water. “Drinking water contaminated with PFAS has plagued communities across this country for too long,” EPA Administrator Michael Regan said in an agency news release announcing…  read on >  read on >

Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight. There were concerns that longer term use of the drugs might raise users’ odds for thyroid cancer, but a Swedish study of more than 435,000 people finds no evidence to support that notion. “Many…  read on >  read on >

A new drug can slash triglyceride levels nearly in half by targeting a genetic driver of high fat levels in the bloodstream, researchers said. The injectable drug, olezarsen, lowered triglyceride levels by 49% at the 50 milligram (mg) dose and by 53% at the 80 mg dose compared to a placebo, researchers reported April 7…  read on >  read on >

New research questions the effectiveness of the U.S. Food and Drug Administration’s accelerated drug approval program after finding that many cancer drugs remain unproven five years later. The study, published Sunday in the Journal of the American Medical Association and presented simultaneously at the American Association of Cancer Research’s annual meeting in San Diego, found…  read on >  read on >

THURSDAY, April 4, 2024 (HealthDayNews) — Following disappointing trial results, the maker of a controversial ALS drug said it is pulling the medication off the market. In a statement issued Thursday, Amylyx Pharmaceuticals said that Relyvrio failed to help patients in a large follow-up study, and the drug “will no longer be available for new…  read on >  read on >